Abstract 2371P
Background
In the phase 3 JAVELIN Bladder 100 trial (NCT02603432), avelumab 1L maintenance therapy + best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free survival (PFS) vs BSC alone in pts with aUC without progression following 1L platinum-based chemotherapy. After ≥2 years of follow-up in all pts, median OS was 23.8 months (95% CI, 19.9-28.8) vs 15.0 months (95% CI, 13.5-18.2), respectively. Avelumab 1L maintenance also had minimal impact on quality of life. Here, we report long-term efficacy and safety outcomes in subgroups based on older age (≥65 years).
Methods
Eligible pts with locally advanced or metastatic UC without progression following 4 to 6 cycles of 1L platinum-based chemotherapy were randomized 1:1 to receive avelumab + BSC (n=350) or BSC alone (n=350). The primary endpoint was OS; secondary endpoints included PFS and safety. For this post hoc analysis, subgroups aged ≥65 to <75 years, ≥75 years, and ≥80 years were analyzed. Pts aged <65 years were not included in this analysis.
Results
At data cutoff (June 4, 2021), median follow-up in both arms was ≥38 months. In the avelumab + BSC and BSC alone arms, age was ≥65 to <75 years in 136 and 163 pts, ≥75 years in 85 and 80 pts, and ≥80 years in 28 and 27 pts, respectively. Across all subgroups, OS and PFS were prolonged with avelumab + BSC vs BSC alone (Table). The table also shows incidence of any-grade and grade ≥3 treatment-related adverse events (TRAEs) in the subgroups.
Conclusions
Long-term outcomes from JAVELIN Bladder 100 confirm prolonged OS and PFS with avelumab + BSC vs BSC alone in older pts. Long-term safety of avelumab 1L maintenance was similar across subgroups, confirming its tolerability. These findings provide further support for avelumab 1L maintenance as standard of care in pts with aUC without progression following 1L platinum-based chemotherapy, including older pts over 65 years old. Table: 2371P
Age | ≥65 to <75 years | ≥75 years | ≥80 years | |||
Arm | Avelumab + BSC (n=136) | BSC (n=163) | Avelumab + BSC (n=85) | BSC (n=80) | Avelumab + BSC (n=28) | BSC (n=27) |
Median OS (95% CI), months | 28.7 (20.9-35.1) | 17.1 (12.9-21.3) | 24.0 (18.6-37.0) | 13.5 (8.6-18.5) | 24.9 (14.1-NE) | 10.0 (7.0-26.9) |
HR for OS (95% CI) | 0.73 (0.543-0.974) | 0.59 (0.401-0.877) | 0.57 (0.284-1.155) | |||
Median PFS by investigator (95% CI), months | 7.4 (3.7-11.2) | 2.8 (1.9-3.7) | 9.2 (5.6-13.3) | 2.2 (1.9-3.7) | 13.8 (5.7-30.3) | 1.9 (1.7-3.7) |
HR for PFS (95% CI) | 0.51 (0.389-0.666) | 0.38 (0.266-0.554) | 0.27 (0.129-0.560) | |||
Any-grade TRAE, n (%)* | 103 (79.2) | 2 (1.2) | 70 (82.4) | 2 (2.6) | 24 (85.7) | 0 |
Grade ≥3 TRAE, n (%)* | 24 (18.5) | 0 | 18 (21.2) | 0 | 9 (32.1) | 0 |
NE, not estimable.∗In treated pts.
Clinical trial identification
NCT02603432; First posted: November 11, 2015.
Editorial acknowledgement
Medical writing support was provided by Lauren O’Brien on behalf of Clinical Thinking and funded by Pfizer and Merck.
Legal entity responsible for the study
The authors.
Funding
This trial was sponsored by Pfizer, as part of an alliance between Pfizer and Merck (CrossRef Funder ID: 10.13039/100009945). This analysis was sponsored by Merck.
Disclosure
S. Gupta: Financial Interests, Personal, Advisory Role: Bristol Myers Squibb, Gilead Sciences, Guardant Health, AVEO, Merck, Pfizer, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Loxo, Lilly, Bayer; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb, Janssen Oncology, Seagen, Gilead Sciences; Financial Interests, Personal, Stocks/Shares: Nektar, Moderna, BioNTech. M.A. Climent Duran: Financial Interests, Personal, Advisory Role: Astellas Pharma, Bayer, Bristol Myers Squibb, Celgene, Eisai, EUSA Pharma, Janssen-Cilag, MSD, Pfizer, Roche/Genentech, Sanofi, Merck; Financial Interests, Personal, Other, Travel and Accommodation Expenses: Ipsen, Janssen, Pfizer, Roche, Merck; Financial Interests, Personal, Other, Honoraria: Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai Europe, EUSA Pharma, Ipsen, Janssen, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Merck; Financial Interests, Personal, Advisory Board: Janssen Oncology. S. Sridhar: Financial Interests, Personal, Advisory Role: Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Janssen, MSD, Pfizer, Roche/Genentech, Seagen; Financial Interests, Institutional, Funding: Bayer, Janssen, Pfizer. T.B. Powles: Financial Interests, Personal, Advisory Role: Bristol Myers Squibb, AstraZeneca, Ipsen, Pfizer, Novartis, Incyte, Seagen, Roche, Exelixis, MSD, Merck, Astellas Pharma, Johnson & Johnson, Eisai; Financial Interests, Personal, Other, Travel, Accommodation, Expenses: Pfizer. J. Bellmunt: Financial Interests, Personal, Advisory Role: Astellas Pharma, AstraZeneca/MedImmune, Bristol Myers Squibb, Genentech, Novartis, Pfizer, Pierre Fabre, Merck; Financial Interests, Personal, Other, Travel and Accommodation Expenses: Ipsen, MSD, Pfizer; Financial Interests, Personal, Royalties: UpToDate; Financial Interests, Personal, Stocks/Shares: Rainier Therapeutics; Financial Interests, Personal, Other, Honoraria: UpToDate; Financial Interests, Institutional, Funding: Millennium, Pfizer, Sanofi, Merck. K. Tyroller: Financial Interests, Personal, Full or part-time Employment: EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA; Financial Interests, Personal, Stocks/Shares: Merck. S. Guenther: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck. A. di Pietro: Financial Interests, Personal, Full or part-time Employment: Pfizer; Financial Interests, Personal, Stocks/Shares: Pfizer; Financial Interests, Personal, Other, Honoraria: Pfizer. P. Grivas: Financial Interests, Personal, Advisory Role: 4D Pharma, Aadi Bioscience, Astellas Pharma, Asieris Pharmaceuticals, AstraZeneca, BostonGene, Bristol Myers Squibb, CG Oncology, Dyania Health, Exelixis, Fresenius Kabi, Genentech/Roche, Gilead Sciences, Guardant Health, ImmunityBio, Infinity Pharmaceuticals, Janssen, Lucence, Merck, Mirati Therapeutics, MSD, Pfizer, PureTech Health, QED Therapeutics, Regeneron, Roche, Seagen, Silverback Therapeutics, Strata Oncology, UroGen Pharma; Financial Interests, Institutional, Funding: Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm Group, G1 Therapeutics, Gilead Sciences, GSK, Merck, Mirati Therapeutics, MSD, Pfizer, QED Therapeutics; Financial Interests, Personal, Advisory Board: G1 Therapeutics.
Resources from the same session
1736P - Young adult lung cancer demands more attention in a low-resource area: Bangladesh perspective
Presenter: Muhammad Rafiqul Islam
Session: Poster session 23
1737P - Use of the predictive risk model LungFlagTM for lung cancer screening in screening in a Spanish reference center: A cost-effectiveness analysis
Presenter: Maria Eugenia Olmedo Garcia
Session: Poster session 23
1738P - Impact of digital platforms on exposure to tobacco and new smoking devices: A survey approach
Presenter: Diego de Haro
Session: Poster session 23
1739P - Lung cancer mortality patterns of tobacco users in the United States: A 21-year analysis (1999-2020)
Presenter: Seif Bugazia
Session: Poster session 23
1740P - Geolocation of respiratory tract cancer and its relationship with chronic exposure to PM2.5 pollutants
Presenter: Moisés González-Escamilla
Session: Poster session 23
1741P - Are physicians aware of lung cancer screening benefits and the importance of implementing this? Data from two public hospitals in Buenos Aires province, Argentina
Presenter: Valentin Vidal
Session: Poster session 23
1742P - Gender differences in incidence trends of early-onset GI cancer: The European perspective
Presenter: Irit Ben-Aharon
Session: Poster session 23
1743P - Bridging the gender gap in oncology: GEORGiNA'S quest for equality in academic research
Presenter: Khalid El Bairi
Session: Poster session 23
1744P - Socioeconomic inequalities in the diagnosis and treatment of colon cancer: A population-based English cancer registry study
Presenter: Benjamin Pickwell-Smith
Session: Poster session 23
1745P - Why do adult patients with cancer abandon treatment in India? A nationwide qualitative study to understand the perspectives of healthcare workers
Presenter: Reshma Ayiraveetil
Session: Poster session 23